Icosavax Inc

NASDAQ ICVX

Data sourced from

and

Download Data

Icosavax Inc Earnings Per Share (EPS), Diluted for the quarter ending September 30, 2023

Icosavax Inc Earnings Per Share (EPS), Diluted is NA for the quarter ending September 30, 2023. Earnings Per Share (EPS), Diluted, is the portion of a company's profit allocated to each outstanding share of common stock, assuming the conversion of all potentially dilutive securities.

Icosavax Inc Earnings Per Share (EPS), Diluted for the quarter ending September 30, 2022 was USD -0.55, a 57.40% change year over year.
Icosavax Inc Earnings Per Share (EPS), Diluted for the quarter ending September 30, 2021 was USD -1.30, a 30.53% change year over year.
Icosavax Inc Earnings Per Share (EPS), Diluted for the quarter ending September 30, 2020 was USD -1.87.

NASDAQ: ICVX

Icosavax Inc

CEO	Mr. Adam K. Simpson
IPO Date	July 29, 2021
Location	United States
Headquarters	1616 Eastlake Avenue East, Seattle, WA, United States, 98102
Employees	60
Sector	Healthcare
Industry	Biotechnology

Description

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.

Key trends